Entera Bio Ltd. develops orally delivered peptide and protein replacement therapies as a clinical-stage biopharmaceutical company. News about ENTX centers on its N-Tab® oral peptide platform and pipeline candidates, including EB613, an oral PTH(1-34) tablet for osteoporosis, and EB612, a long-acting oral PTH peptide replacement tablet for hypoparathyroidism.
Recurring updates also cover FDA communications and clinical-development plans, OPKO collaboration activity, financial results, private placements and warrant-linked capital actions, board and governance changes, and medical-community discussions around osteoporosis and oral anabolic therapy.
Entera Bio (NASDAQ: ENTX) appointed Dr. Juan Camilo Arjona Ferreira to its Board of Directors, effective December 1, 2026. He will succeed Haya Taitel, who is stepping down from the board.
Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon. He brings more than 20 years of global clinical development experience, including previous roles at Myovant Sciences, Shionogi and Merck, with a focus on women’s health.
Entera Bio (ENTX) presented exploratory EB613 osteoporosis results and a planned Phase 3 study design at the ASBMR 2026 meeting. A post-hoc analysis of the six-month Phase 2 trial examined EB613 2.5 mg daily. In women with osteoporosis at the measured site, placebo-adjusted bone mineral density (BMD) gains were 4.23% at the total hip (n=6) and 4.22% at the lumbar spine (n=9), versus 1.02% (n=15) and 1.59% (n=12), respectively, in women with less severe bone loss. Bone turnover marker changes were somewhat larger and more persistent in the osteoporosis subgroup. These findings are exploratory and hypothesis-generating.
The planned Phase 3 study would randomize approximately 900 participants 2:1 to EB613 or placebo for 12 months. Its primary efficacy measure is total hip BMD change at Month 12; secondary measures cover other skeletal sites and earlier assessments.
Entera Bio (NASDAQ: ENTX) will present its planned EB613 Phase 3 study design at the ASBMR annual meeting on October 11, 2026. The late-breaking poster presentation will outline a single, randomized, double-blind, placebo-controlled trial in postmenopausal women with osteoporosis. EB613 is an oral PTH(1-34) tablet being developed for osteoporosis.
Dr. Felicia Cosman of Columbia University will lead the presentation, scheduled for 2:00–3:30 p.m. ET. The meeting runs October 9–12 in Boston. Entera will also present EB613 Phase 2 findings in a plenary poster session on October 9, from 5:30–7:00 p.m. ET, and Poster Session II on October 11, from 2:00–3:30 p.m. ET.
Entera Bio (NASDAQ: ENTX) has appointed Laura Hamill to its Board of Directors, effective December 1, 2026, succeeding Yonatan Malca.
Hamill brings more than 35 years of global commercial, market access and business leadership experience. She most recently served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, leading approximately 2,500 employees responsible for $22 billion in annual revenue. Previously, she spent nearly two decades at Amgen, including overseeing commercial activities and supporting functions representing approximately 80% of Amgen’s revenue.
Entera expects her experience to support commercial preparedness for its osteoporosis candidate EB613 and broader pipeline advancement. Malca is stepping down after 16 years of service.
Entera (NASDAQ: ENTX) announced that CEO Miranda Toledano will present at three fall 2026 investor conferences: the Cantor Global Healthcare Conference on September 10 in New York, the Guggenheim Securities 3rd Annual Healthcare Innovation Conference on November 9 in Boston, and the Evercore ISI 9th Annual Healthcare Conference from November 30–December 2 in Miami.
Entera is a clinical-stage company developing oral peptide and protein replacement therapies using its N-Tab® platform, with lead candidate EB613 for osteoporosis and additional programs in hypoparathyroidism, obesity, metabolic syndromes, and rare malabsorption conditions.
Entera Bio (NASDAQ: ENTX) appointed Riccardo Paolo Camisasca, M.D., as Chief Medical Officer, adding more than 30 years of global pharmaceutical R&D, clinical development and medical affairs experience from roles at Sumitomo Pharma, Takeda, Novartis and others. The hire strengthens Entera’s clinical leadership ahead of the planned Phase 3 program for EB613.
EB613, an oral once-daily PTH(1-34) tablet for osteoporosis, previously completed a 6‑month, 161‑patient placebo‑controlled Phase 2 study that met all biomarker and bone mineral density endpoints without significant safety concerns. According to Entera, EB613 showed rapid bone formation marker increases, BMD gains at multiple skeletal sites and 3D‑DXA improvements consistent with published subcutaneous teriparatide data.
Entera is also advancing EB612 for hypoparathyroidism, an oral oxyntomodulin for obesity and metabolic syndromes, and an oral GLP‑2 tablet for rare malabsorption conditions in collaboration with OPKO Health.
Entera (NASDAQ: ENTX) reported second quarter 2026 results and significant pipeline and financing milestones. The FDA accepted the company’s plan for a single 12‑month, ~750‑patient, randomized Phase 3 registrational trial of oral anabolic tablet EB613 in postmenopausal osteoporosis, supporting a potential 505(b)(2) NDA with a scientific bridge to Forteo. Phase 3 initiation is planned for late 2026, with topline data expected in 2H 2028.
Preclinical data for EB612 in hypoparathyroidism and non‑human primate data for EB618 in obesity were presented at ENDO 2026. Post‑quarter, Entera closed an oversubscribed $275 million private placement led by BVF, expected to fund EB613 through NDA submission and extend cash runway into 2030. Q2 2026 net loss was $7.3 million with no revenues.
Entera Bio (NASDAQ: ENTX) announced that post-hoc data from its Phase 2 trial of EB613, an oral PTH(1-34) tablet being developed as the first oral anabolic osteoporosis treatment, has been selected for a Plenary Poster Presentation and a second poster at the ASBMR 2026 Annual Meeting in Boston, October 9–12, 2026.
The sensitivity analysis evaluates EB613’s anabolic effects on bone mineral density and bone turnover markers at 6 months in postmenopausal women with osteoporosis at high fracture risk. According to Entera, the 161-patient, 6‑month, placebo-controlled Phase 2 study met biomarker and BMD endpoints without significant safety concerns, showing dose‑proportional increases in bone formation markers and increases in lumbar spine, total hip, and femoral neck BMD. Entera plans a single randomized, double‑blind, placebo‑controlled Phase 3 trial in approximately 750 postmenopausal women with osteoporosis to support a potential NDA submission for EB613.
Entera Bio (NASDAQ: ENTX) announced that CEO Miranda Toledano will participate in a fireside chat and 1x1 meetings at the Canaccord Genuity 46th Annual Growth Conference. The fireside chat is scheduled for August 12, 2026 at 1:00 p.m. Eastern Time at the InterContinental Boston Hotel, with the overall event taking place in person from August 11–13, 2026.
A live webcast and presentation slides will be accessible via the provided link, with a replay available for 365 days. Entera is a clinical-stage company developing oral peptide and protein replacement therapies, including lead osteoporosis candidate EB613, which met primary and secondary endpoints in a Phase 2 study.
Entera Bio (NASDAQ: ENTX) completed an oversubscribed $275 million private placement (PIPE), for which Greenberg Traurig advised the company. According to Entera Bio, the financing is expected to extend its cash runway into 2030 and fully support Phase 3 registrational studies of EB613, an oral PTH (1-34) tablet in development for osteoporosis.
According to data compiled by Arx Capital Markets, this is the largest publicly disclosed Israeli biotech PIPE on record and the ninth largest Israeli PIPE overall. The Greenberg Traurig deal team was led from Miami with support from the firm’s Tel Aviv office.